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Abstract
Background: Bacterial endotoxin, long recognized as a potent pro-inflammatory mediator in acute infectious
processes, has more recently been identified as a risk factor for atherosclerosis and other cardiovascular diseases.
When endotoxin enters the bloodstream, one of the first cells activated is the circulating monocyte, which exhibits
a wide range of pro-inflammatory responses.
Methods: We studied the effect of low doses of E. coli LPS on IL-8 release and superoxide formation by freshly
isolated human peripheral blood mononuclear cells (PBMC).
Results: IL-8 release was consistently detectable at 10 pg/ml of endotoxin, reaching a maximum at 1 ng/ml, and
was exclusively produced by monocytes; the lymphocytes neither produced IL-8, nor affected monocyte IL-8
release. Superoxide production was detectable at 30 pg/ml of endotoxin, reaching a maximum at 3 ng/ml. Peak
respiratory burst activity was seen at 15-20 min, and superoxide levels returned to baseline by 1 h. IL-8 release was
dependent on both membrane-associated CD14 (mCD14) and Toll-like receptor 4 (TLR4. Superoxide production
was dependent on the presence of LBP, but was not significantly affected by a blocking antibody to TLR4.
Moreover, treatment with lovastatin inhibited LPS-dependent IL-8 release and superoxide production.
Conclusions: These findings suggest that IL-8 release and the respiratory burst are regulated by distinct endotoxin-
dependent signaling pathways in PBMC in low level of endotoxin exposure. Selectively modulating these pathways
could lead to new approaches to treat chronic inflammatory diseases, such as atherosclerosis, while preserving the
capacity of monocytes to respond to acute bacterial infections.
Background
Bacterial endotoxin, long recognized as a potent pro-
inflammatory mediator in acute infectious processes, has
more recently been identified as a risk factor for athero-
sclerosis and other forms of cardiovascular disease [1-3].
In endotoxemia, one of the first cells to elicit a pro-
inflammatory response is the circulating monocyte.
Monocytes are known to respond to extremely low levels
of endotoxin (pg/ml) [3], producing a wide array of che-
mokines and cytokines, and releasing cytotoxic levels of
reactive oxygen species (ROS) via the respiratory burst.
The resulting inflammatory process is initially beneficial
to the host as a means of protection against invading
microorganisms; however, if not resolved, chronic
damage to host tissues can ensue. In this respect, a grow-
ing body of evidence suggests that the persistent low-
level inflammation associated with chronic, subclinical
infections (e.g., periodontitis, diverticulitis, or smoker’s
bronchitis) may also play a role in exacerbation of vascu-
lar diseases such as atherosclerosis [1].
The classic endotoxin signaling pathway has been
shown to involve LBP, CD14, MD-2, and Toll-like
receptor 4 (TLR4) [3-6]. It was commonly believed that
all of these elements are required for initiation of endo-
toxin signaling [7], Although this pathway has been
extensively documented in many model systems, there is
* Correspondence: andra.blomkalns@uc.edu
† Contributed equally
1Department of Emergency Medicine, University of Cincinnati, Cincinnati, OH
USA
Full list of author information is available at the end of the article
Blomkalns et al. Journal of Inflammation 2011, 8:4
http://www.journal-inflammation.com/content/8/1/4
© 2011 Blomkalns et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.evidence that alternate signaling pathways may exist
in some cells. For example, endotoxin concentrations
>100 ng/ml have been shown to activate host cells by
mechanisms independent of the CD14-TLR4 path-
way [8-10] Moreover, rapid production of ROS in LPS-
simulated (100 ng/mL) macrophages has been shown to
be partly dependent on the activation of cytoplasmic
GTPase Rac1, a known activator of NOX-1 oxidase
enzyme activity [11]. The above findings may be perti-
nent to mechanisms of LPS signaling in the setting of
acute sepsis. In contrast, relatively little is known about
potential alternative signaling pathways in humans acti-
vated by lower levels of endotoxin pertinent to chronic
inflammatory diseases such as atherosclerosis.
To address this question, we designed experiments
using freshly isolated human peripheral blood mononuc-
lear cells (PBMC) to compare and contrast the effects of
low levels of endotoxin (≤1 ng/ml) on two inflammatory
responses, IL-8 release and superoxide production. Our
d a t as u g g e s tt h a tt w od i s t i n ct signaling pathways are
involved in eliciting these responses. The presence of
these two pathways in monocytes raises the possibility
of targeting therapeutic interventions to modulate speci-
fic pro-inflammatory responses involved in chronic
inflammatory diseases such as atherosclerosis.
Methods
Materials
The endotoxin (LPS) from E. coli K12 LCD25 was pur-
chased from List Biological Laboratories. All LPS pre-
parations from List Biological Laboratories, Inc., are
essentially free of nucleic acid and protein and are che-
mically characterized with respect to their phosphate
and 2-keto-3-deoxyoctonate (KDO) contents. For these
studies, the purchased LPS preparation was further puri-
fied by a phenol re-extraction method to eliminate resi-
dual protein contamination prior to use in our
experimental models.
MEM-18, an antibody that binds to the endotoxin-bind-
ing site of CD14, was purchased from Accurate Chemical
(Westbury, NY). Blocking antibodies to TLR4 (HTA-125)
and to CD11, CD11b, and CD18 were purchased from
eBioscience (San Diego, CA). Recombinant LBP was pur-
chased from R&D Systems (Minneapolis, MN). Lucigenin
(bis-N-methylacridinium nitrate), and lovastatin were pur-
chased from Sigma Aldrich (St. Louis, MO). Human
serum albumin (HSA) was obtained from the University of
Iowa Hospital pharmacy. Lipooligosaccharide (LOS) from
N. meningitides was generously provided by Dr. Michael
Apicella (University of Iowa).
PBMC isolation
Heparinized venous blood was obtained from healthy
volunteers (n = 4) in accordance with a protocol
approved by the Institutional Review Board for Human
Subjects at the University of Iowa. Peripheral blood
mononuclear cells (PBMC) were isolated using dextran
sedimentation and Hypaque-Ficoll density-gradient
separation followed by hypotonic lysis of erythrocytes as
previously described [12]. Generally monocytes comprise
approximately 10% of the isolated PBMCs. Purified
PBMC were resuspended in incubation buffer (sterile
pyrogen-free Hanks balanced salt solution [HBSS; Bio-
Whittaker] supplemented with 0.1% D-glucose [HBSS/
G] and 0.1% human serum albumin [HSA]) and kept on
ice until use.
IL-8 release
For experiments using whole PBMC, cells were sus-
pended at 1 × 10
7 PBMC/ml in incubation buffer with
2× the indicated final concentration of LBP. Aliquots
(100 μl) of cell suspension were then placed in indivi-
dual wells of a 48-well tissue culture plate, and 100 μlo f
2× the indicated final concentration of endotoxin was
added to the wells.
For studies to determine the relative contribution of
the monocyte and lymphocyte subpopulations, 1 × 10
6
PBMC in 100 μl of HBSS/G were placed in wells of a
48-well plate, and cultures were incubated at 37°C for
2 h to allow the monocytes to adhere. The buffer con-
taining the non-adherent cells (primarily lymphocytes)
was then removed and pooled. The cells were pelleted
and resuspended in incubation buffer (1 × 10
7/ml) with
2× the indicated concentration of LBP. 100 μl of cell
suspension was placed in individual wells of a 48-well
plate, and 100 μl of 2× the indicated final concentration
of endotoxin was then added to the wells. The adherent
cells were gently washed twice with HBSS at 37°C con-
taining 0.1% HSA; 200 μl of incubation buffer contain-
ing indicated concentrations of endotoxin and LBP was
then added to each well. For all studies, cultures were
incubated in a 37°C for 6 h. At the end of this incuba-
tion period, the media were transferred to microfuge
tubes and centrifuged for 2 min at 5,000 rpm. Superna-
tants from these samples were then transferred to new
microfuge tubes and frozen until analysis. IL-8 was mea-
sured by ELISA, using matched antibodies from R&D
Systems as described previously. The lower limit of
detection for this IL-8 assay was 15 pg/ml [13].
Lucigenin-enhanced chemiluminescence
Lucigenin-enhanced chemiluminescence was measured
by a modification of the method of Allen et al. [14]
using a microplate luminometer (FLUOStar Optima,
BMG Labtech, Durham, NC). All reagents were pre-
pared using sterile pyrogen-free injectable solutions
obtained from the hospital pharmacy, and all compo-
nents of the reaction were combined on ice to prevent
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PBMC were diluted to a final concentration of 1.0 ×
10
7/ml in ice-cold incubation buffer with 2× the indi-
cated final concentration of LBP, and 100 μla l i q u o t so f
the cell suspension were placed in wells of a 96-well
Optiplate (Perkin Elmer, Boston, MA). Lucigenin (final
concentration of 1 × 10
-4 M) and 2× the indicated final
concentration of endotoxin were then added to each
well. The plates were then placed in the luminometer
and two-sec readings were taken at 37°C every 2 min
for 180 min. The resulting readings in relative light
units (LU) were summed to provide a measure of activ-
ity. Values are expressed as the sum of the readings in
arbitrary light units (LU) collected over the 2 h mea-
surement, and represent the mean + SEM for 4 replicate
samples.
Inhibitor and blocking antibody studies
To determine the effect of lovastatin, cells were pre-
incubated overnight at 37°C with 1.5 μMo ft h ed r u gi n
incubation buffer, and then stimulated with the indi-
cated concentration of endotoxin. To test the effect of
blocking antibodies, 1 × 10
6 PBMC in 100 μl of incuba-
tion buffer with the indicated concentration of LBP and
with the indicated antibody were incubated for 30 min
at 37°C prior to endotoxin addition. Antibodies tested
were: 1 μg/well MEM18, anti-CD14 (Leinco Technolo-
gies), and 2 μg/well HTA-125, anti-TLR4.
Statistics
All statistical analyses were performed with SigmaStat
version 3.1 (SPSS Inc., Chicago, IL). Data are expressed
as means ± SEM and have been compared by Student’s
t-test and repeated measures ANOVA when appropriate.
*P < 0.05 was considered to be statistically significant.
Results
Effect of endotoxin on IL-8 release by human PBMC
Figure 1 demonstrates that LPS concentrations as low as
3 pg/mL resulted in measurable IL-8 production (2.10
ng of IL-8 per million total PBMCs) from freshly iso-
lated human PBMCs (squares) under the tested condi-
tions. The response is significant at LPS concentrations
of 100 pg/mL, achieving a maximal level at ~1 ng/mL.
This figure also shows that the IL-8 release is due to
adherent cells (monocytes, diamonds). Non-adherent
cells (primarily lymphocytes, circles) produced little or
no measurable IL-8 over the concentration range tested,
nor did their presence appear to affect monocyte IL-8
release. Similar results were obtained in experiments
using N. meningitidis lipooligosaccharide (LOS; data not
shown).
Endotoxin signaling reportedly requires CD14 (mem-
brane or soluble), MD-2, and TLR4 [4,15,16]. To
determine whether these proteins are involved in LPS-
induced IL-8 release by human PBMC, we used blocking
antibodies. Figure 2 shows that antibodies to CD14
(MEM-18; Figure 2A) and to TLR4 (HTA-125; Figure
2B) inhibited LPS-induced IL-8 release; however, the
HTA-125 antibody was less effective at higher LPS con-
centrations. To confirm the specificity of these antibo-
dies, we performed parallel experiments with TNFa as a
stimulus. Neither MEM-18 nor HTA-125 inhibited
TNFa-stimulated IL-8 release (data not shown).
Effect of increasing LBP on endotoxin-dependent IL-8
release by monocytes and macrophages
LBP is a 60 kDa lipid/phospholipid binding and transfer
protein with fairly broad specificity [17,18]. Its role with
respect to endotoxin is to catalyze the delivery and trans-
fer of monomeric endotoxin to either membrane-bound
(mCD14) or soluble CD14 (sCD14) for cellular activation.
Plasma LBP levels have been shown to increase by 10- to
30-fold during acute inflammatory responses [19]. Phy-
siological levels of LBP facilitate inflammation, while the
high levels of LBP in acute inflammatory responses are
inhibitory [20]. Therefore, we tested the effect of increas-
ing LBP concentrations on LPS-induced IL-8 release by
PBMC (Figure 3). Surprisingly, LPS-induced IL-8 release
by PBMCs did not change over the range of LPS concen-
trations tested (Figure 3A).
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Figure 1 Effect of LPS on IL-8 release by adherent (monocytes)
and non-adherent (lymphocytes) cells. Freshly isolated human
PBMC (~1.0 × 10
6 total cells/well, ~100,000 monocytes), as well as
adherent and non-adherent cell fractions from the same donor,
were prepared as described in Methods in 200 μl of incubation
buffer, 100 ng/ml of LBP, and the indicated concentration of
endotoxin. Cultures were then incubated at 37°C for 6 h. At the end
of the incubation period, cells were pelleted, and buffer samples
were frozen at -20°C for subsequent IL-8 analysis by ELISA. Data are
expressed as the mean ± S.E.M. of triplicate samples; error bars for
some conditions were so small they are obscured by the symbols.
**p < 0.001 for total PBMC and non-adherent cells relative to the
no LPS control, and in comparison with adherent cells. Similar
results were seen in 3 independent experiments and in a parallel
series of experiments with N. meningitidis LOS (data not shown).
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binding for resultant cellular activation. We hypothe-
sized that an endotoxin-binding protein other than LBP
was involved in this response. Studies by Gioannini
et al. [21] have found that albumin is an essential and
specific facilitator of LBP/sCD14-induced LOS disaggre-
gation. To determine whether albumin alone present in
our medium was sufficient for monocytic cellular activa-
tion, we tested the effect of decreasing albumin concen-
trations (from 100 nM to 0 nM) on IL-8 release. We
saw decreasing IL-8 release with decreasing albumin
concentrations (data not shown), suggesting an albumin
dependent reaction and is consistent with the known
interactions of albumin and endotoxin.
Since macrophages have been reported to exhibit an
LBP-dependent inflammatory response [18], we next com-
pared the effect of increasing LBP on LPS-induced IL-8
release by freshly isolated PBMC, and by 3-day differen-
tiated macrophages from the same donor (Figure 3B). As
previously reported, there was an LBP-dependent increase
in IL-8 release by differentiated macrophages (Figure 3B,
circles) that was followed by a decrease at higher LBP con-
centrations (3 ng/ml); macrophages produced significantly
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Figure 2 Effect of blocking antibodies on endotoxin-dependent
IL-8 release by PBMC. Freshly isolated human PBMC (~1.0 × 10
6
total cells/well, 100,000 monocytes) were prepared as described in
Methods in 100 μl of incubation buffer containing 100 ng/ml LBP,
and (A) 1 μg/well of non-immune mouse IgG or MEM-18 (anti-
CD14), or (B) 2 μg/well non-immune mouse IgG or HTA-125 (anti-
TLR4). Cultures were then pre-incubated at 37°C for 30 min, and 100
μl of 2× the final endotoxin concentration in incubation buffer was
added to the wells. Cultures were incubated at 37°C for 6 h. At the
end of the incubation period, samples were collected and frozen for
subsequent IL-8 analysis by ELISA. Data are expressed as the mean
± S.E.M. of triplicate samples; error bars for some conditions were so
small they are obscured by the symbols. (A) *p < 0.05, **p < 0.001
for mouse IgG values relative to MEM-18 values for the same LPS
concentration. (B) *p < 0.05, **p < 0.001 for mouse IgG values
relative to HTA-125 values for the same LPS concentration. Similar
results were seen in 3 independent experiments.
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Figure 3 Effect of LBP on endotoxin-dependent IL-8 release by
PBMC. (A) Freshly isolated human PBMC (~1.0 × 10
6 total cells/well,
100,000 monocytes) were prepared as described in Methods in 200
μl of incubation buffer with and without 100 ng/ml LBP, and with
the indicated concentration of endotoxin. (B) PBMC and partially
differentiated macrophages (~100,000 cells/well; see Methods) from
the same donor were prepared in 200 μl of the same buffer
containing 100 pg/ml of endotoxin and the indicated concentration
of LBP. All cultures were then incubated for 6 h. At the end of the
incubation period, samples were collected and frozen for
subsequent IL-8 analysis by ELISA. Data are expressed as the mean
± S.E.M. of triplicate samples; error bars for some conditions were so
small they are obscured by the symbols. (A) *p < 0.05, **p < 0.001
relative to the no LPS control. There were no significant differences
between the presence and absence of LBP. (B) *p < 0.05 relative to
the no LBP control. Similar results were seen in 3 independent
experiments.
Blomkalns et al. Journal of Inflammation 2011, 8:4
http://www.journal-inflammation.com/content/8/1/4
Page 4 of 11less IL-8 relative to PBMC at all LBP concentrations
tested. In contrast, increasing LBP had little or no effect
on LPS-mediated IL-8 release by freshly isolated mono-
cytes from the same donor (Figure 3B, squares). Similar
findings were observed in studies using N. meningitidis
LOS (data not shown).
Effect of endotoxin on the respiratory burst in PBMC
As part of the innate immune response to pathogens,
monocytes reduce molecular oxygen to superoxide
anion, a process known as the respiratory burst. To
determine the effect of LPS on the respiratory burst in
PBMC, we used lucigenin-enhanced chemiluminescence.
Figure 4A demonstrates that LPS caused a concentra-
tion-dependent increase in superoxide production. As
with IL-8 release (Figure 1), superoxide release by
PBMC is due primarily to the adherent (monocyte) sub-
population of cells, rather than the non-adherent lym-
phocytes (data not shown).
Effect of increasing LBP on the LPS-dependent respiratory
burst
To determine the signaling pathways involved in the
respiratory burst, we first tested the effect of increasing
concentrations of LBP. Whereas LPS-dependent IL-8
release by PBMC was LBP-independent (Figure 3A),
superoxide production was significantly enhanced by
LBP (Figure 4B, squares). Moreover, even at LBP con-
centrations comparable to those seen in the acute phase
response (> 1 μg/ml), LBP was stimulatory, not inhibi-
tory (data not shown). While increasing concentrations
of LBP affected the magnitude of the response, they did
not significantly alter the kinetics of the response, with
maximal superoxide production occurring at ~15-20
minutes, and a return to near baseline levels by 1 h
(data not shown).
Effects of antibodies to TLR4 and CD14 on the
LPS-dependent respiratory burst
As noted above, LPS-induced IL-8 release was blocked
by antibodies to both CD14 and TLR4 (Figure 2). In
contrast, the TLR4 blocking antibody HTA-125, at a
concentration that produced a marked rightward shift in
dose-dependent IL-8 release induced by endotoxin, had
little impact on the magnitude (Figure 5) or the kinetics
(data not shown) of endotoxin-induced superoxide pro-
duction. The effect of MEM-18, a blocking antibody to
CD14, was more variable. When used at a concentration
that completely blocked endotoxin-induced IL-8 release,
MEM-18 partially inhibited endotoxin-dependent super-
oxide production by monocytes from most donors, ran-
ging from ≅ 10% to 100% inhibition, with an average of
55% (n = 4 donors, data not shown). The basis for this
donor variability is unknown, but may reflect the
relative abundance of membrane-bound CD14, donor-
specific differences in antibody-CD14 interactions, and/
or the presence of other membrane proteins that substi-
tute as cofactors for endotoxin-dependent activation of
the NADPH oxidase complex.
To test the possibility that members of the integrin
family might contribute to endotoxin-induced superoxide
release by monocytes, we performed a series of prelimin-
ary experiments in which we incubated PBMC with anti-
bodies to CD11b/CD18 and CD11c/CD18 for 30 min
before the addition of endotoxin. Neither antibody alone
had an appreciable effect on endotoxin-induced
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Figure 4 Effect of LBP on endotoxin-induced superoxide
production by PBMC. (A) Freshly isolated human PBMC (~1.0 ×
10
6 total cells/well, 100,000 monocytes) were placed on ice in
individual wells of a 96-well white Optiplate in a total volume of
200 μl of incubation buffer containing 0.1 mM lucigenin, 100 ng/ml
of LBP, and the indicated concentration of endotoxin. (B) PBMC
were prepared under the same conditions with and without 100
ng/ml LBP and the indicated concentration of endotoxin. The plates
were then placed in the luminometer and two-sec readings were
taken at 37°C every 2 min for 180 min. The resulting readings in
relative light units (LU) were summed to provide a measure of
activity. Data are expressed as total LU (in thousands) per 100,000
monocytes and represent the mean ± S.E.M. of 4 replicate samples;
error bars for some conditions were so small they are obscured by
the symbols. (A) **p < 0.001 relative to the no LPS control. (B)
*p < 0.05, **p < 0.001 for the 100 ng/ml LBP values relative to the
no LBP values at the same LPS concentration. Similar results were
seen in 3 independent experiments, and in a parallel series of
experiments with N. meningitidis LOS (not shown).
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both antibodies were used together, superoxide produc-
tion was significantly reduced. Moreover, when both
anti-integrin antibodies were combined with MEM-18,
superoxide production was reduced to near-baseline
levels in some donors, although this effect was not seen
consistently.
Effect of statins on endotoxin-dependent responses
In addition to their lipid-lowering properties, statins
have recently been shown to induce anti-inflammatory
effects in a number of model systems including those
using human monocytes [22-24]. In particular, their
ability to modulate TLR-4 expression is being investi-
gated in the treatment of sepsis and septic shock [25].
Moreover, pertinent to vascular biology, our laboratory
recently showed that statins inhibit LPS-induced pro-
inflammatory signaling in human blood vessels and in
human coronary artery endothelial and smooth muscle
cells, and that this effect is due to inhibition of gera-
nylgeranylation of one or more proteins in the proxi-
mal part of the endotoxin signaling pathway [26,27].
Thus, we tested whether statins could inhibit LPS-
dependent pro-inflammatory responses in monocytes.
Figure 6 shows that both IL-8 release (Figure 6A) and
superoxide production (Figure 6B) are inhibited by
1.5 μMo fl o v a s t a t i n .
Discussion
Taken together, our results suggest that two important
pro-inflammatory responses to low level endotoxin, IL-8
release and superoxide production, are activated by two
distinct signaling pathways in monocytes freshly isolated
from healthy human donors (Table 1). One is the rapid
(minutes) endotoxin mediated oxidative burst leading to
production of the reactive oxygen species superoxide
anion by the NADPH oxidase complex. The other is
release of the pro-inflammatory cytokine IL-8, involving
activation of multiple transcription factors including
NF-B. We found that the endotoxin-mediated respira-
tory burst is LBP-dependent yet an anti-TLR4 antibody
had no effect on the endotoxin-mediated respiratory
burst as measured here. As inhibition by the CD14
blocking antibody was somewhat variable, there may a
component of the activation pathway that is CD14 inde-
pendent. Contrastingly, in our experimental conditions
IL-8 release appears to be LBP-independent, CD14- and
TLR4-dependent.
There is ample evidence for multiple endotoxin signal-
ing pathways. Best characterized is the pathway in which
LBP facilitates the transfer of endotoxin monomers to
CD14, which in turn presents the endotoxin monomer to
the MD-2/TLR4 complex [28-32]. The transmembrane
domain of TLR4 then transmits the signal via as e r i e so f
adapter proteins and kinases (e.g., MyD88, IRAK, TRAF6,
NIK, IB, and NFB) to the interior of the cell and ulti-
mately to the nucleus, resulting in gene expression. How-
ever, a number of reports in recent years have suggested
the existence of alternate signaling pathways [33].
Studies using LBP knockout mice are consistent with
a physiologically relevant LBP-independent inflamma-
tory response. While whole blood from these animals
was 1000-fold less responsive to endotoxin in vitro stu-
dies, nevertheless when the mice were injected with
LPS, no significant differences between wild-type and
LBP knockout mice (as measured by TNF release) were
observed [34]. In addition, responses to LPS can also be
affected by LBP concentration and the presence or
absence of other serum proteins [20,35-38]. Thompson
et al. demonstrated in THP-1 cells that adding high-
density lipoprotein (HDL) augmented the response to
LPS in otherwise inhibitory LBP concentration condi-
tions. Interactions may also take place between TLR4
and HMGB1 as indicated by Youn et al.[ 3 9 ] .I no u r
specific set of experimental circumstances, we found
that LPS-induced IL-8 release by monocytes was LBP-
independent (Table 1), although in repeated experi-
ments, this finding was in contrast to results with differ-
entiated macrophages from the same donor. This might
be explained by the limiting stoichiometry and molar
relationships between relative amounts of endotoxin,
m
o
n
o
c
y
t
e
s
60
50
70 Mouse IgG
HTA-125
X
 
1
0
3
)
/
1
0
0
,
0
0
0
m
20
40
30
50
L
U
 
(
X
0
10
0 30 100 1000 3000
LPS (pg/ml)
Figure 5 Effect of anti-TLR4 blocking antibody on endotoxin-
induced superoxide production by PBMC. Human PBMC (~1.0 ×
10
6 total cells/well, 100,000 monocytes) were prepared in 100 μlo f
incubation buffer containing 2 μg/well of mouse non-immune IgG or
of HTA-125, and were placed in individual wells of a 96-well white
Optiplate. Plates were incubated at 37°C for 30 min. Plates were then
cooled on ice, and 100 μl of incubation buffer containing 0.2 mM
lucigenin and 2× the final indicated concentration of endotoxin was
added to the wells. The plates were then placed in the luminometer
and two-sec readings were taken at 37°C every 2 min for 180 min.
The resulting readings in relative light units (LU) were summed to
provide a measure of activity. Data are expressed as total LU (in
thousands) per 100,000 monocytes and represent the mean of
duplicate samples. There were no significant differences between the
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Figure 6 Lovastatin inhibits endotoxin-induced IL-8 release and superoxide production. Freshly isolated PBMC (~1.0 × 10
6 total cells/well,
100,000 monocytes) were prepared in 200 μl of incubation buffer with and without 1.5 μM lovastatin, and samples were incubated at 37°C for
16 h. (A) Cells were pelleted, washed gently, and resuspended in 200 μl of incubation buffer containing 100 ng/mL of LBP, and the indicated
concentration of endotoxin. Cultures were then incubated at 37 °C for 6 h. At the end of the incubation period, cells were pelleted, and buffer
samples were frozen at -20°C for subsequent IL-8 analysis by ELISA. Data are expressed as the mean ± S.E.M. of triplicate samples. (B) Cells were
pelleted, washed gently, and resuspended on ice in individual wells of a 96-well white Optiplate in 200 μl of HBSS/0.1% HSA/0.1% G containing
100 ng/mL of LBP, 0.1 mM lucigenin, and the indicated concentration of endotoxin. The plates were then placed in the luminometer and two-
sec readings were taken at 37°C every 2 min for 180 min. The resulting readings in relative light units (LU) were summed to provide a measure
of activity. Data are expressed as total LU (in thousands) per 100,000 monocytes and represent the mean ± S.E.M. of 4 replicate samples; error
bars for some conditions were so small they are obscured by the symbols. (A) **p < 0.001 for the no lovastatin control relative to the lovastatin
value at the same LPS concentration. (B) *p < 0.05, **p < 0.001 for the no lovastatin control relative to the lovastatin value at the same LPS
concentration. Similar results to A and B were seen in 3 independent experiments.
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tration of LPS increases, the ratio of LBP to LPS
decreases, and activation increases. It is possible that in
our monocyte isolation, inadequate CD14 or TLR4
expression may have limited cellular activation and IL-8
release. Furthermore, this would also explain why results
from differentiated macrophages, with likely a greater
expression of CD14, contrasted with the previous results
in monocytes from the same donor. We also observed
decreasing LPS-induced IL-8 release with decreasing
albumin concentrations (data not shown), suggesting
that the human serum albumin in our incubation buffer
(and in plasma) was facilitating endotoxin-binding and
delivery in our experimental model [21]. It is possible
from what is known from our studies as well as others
that serum proteins may variably contribute or inhibit
LPS monomer delivery and hence LPS stimulatory activ-
ity, depending on the experimental and/or physiologic
conditions.
To determine whether CD14 mediated LPS-induced
IL-8 release or the respiratory burst in freshly isolated
PBMC, we performed studies with the anti-CD14 block-
ing antibody MEM-18, which binds to an epitope on the
endotoxin-binding site of CD14. MEM-18 completely
inhibited IL-8 release; however, the ability of the anti-
body to block the respiratory burst was highly variable
(ranging from approximately 10% to 100%) and
appeared to be specific to individual donors (Table 1).
Other investigators have reported evidence of CD14-
independent signaling, particularly with relatively high
(> 100 ng/ml) concentrations of endotoxin [8-10].
Human and murine responses to LPS differ in that the
concentrations of endotoxin challenge necessary to elicit
responses in mice are much greater [41]. For instance,
Maitra et al. demonstrated the contribution of IRAK-1,
a known activator of NOX-1 enzymatic activity, in the
rapid generation of ROS induced by LPS (100 ng/mL) in
murine cells [11]. Perera et al. found a CD14-indepen-
dent signaling pathway in macrophages from CD14-
knockout mice [42]. In this model system, cytokine
release in response to low doses of endotoxin (1 or 10
ng/ml) showed an absolute requirement for CD14
(either the membrane-bound or soluble form, as found
in serum); however, at concentrations of 1 μg/ml or
higher, endotoxin induced equal or greater production
of TNF-a and IL-1b in CD14-knockout as compared to
wild-type mice. Kimura et al. also found evidence of a
CD14-independent endotoxin signaling pathway in a
murine B cell line [43]. In these experiments, IL-6
mRNA expression as well as
3H-thymidine incorpora-
tion as a measure of cellular proliferation were increased
upon stimulation with endotoxin at 1 μg/ml even in the
presence of anti-murine CD14 monoclonal antibody.
The potential complexity of endotoxin signaling is
suggested by the model of a CD14 receptor complex
proposed by Triantafilou et al. [8,44,45]. Using fluores-
cence recovery after photobleaching method (FRAP),
these authors showed that endotoxin initially binds to
CD14, a GPI-anchored receptor, before being trans-
ferred to other receptors such as MD-2. The MD-2:LPS
complex associates with the TLR4 ectodomain for signal
transduction [5,32]. Interestingly, there is evidence to
suggest that additional receptors may play a role in the
transmembrane signal transduction. These include
CD11/CD18 integrins, the CD55 receptor, and a recep-
tor cluster consisting of four different molecules (Heat
shock proteins 70 and 90, chemokine receptor 4, and
growth differentiation factor 5).
One possible mechanism for the partially CD14-inde-
pendent signaling we observed is through the leukocyte
integrin transmembrane receptor CD11/CD18 family
[46-49]. There are three subtypes of this receptor. CD11a/
CD18 participates in leukocyte-endothelial cell interaction
and is found in all white cells. CD11b/CD18 is found
mainly on monocytes and neutrophils and functions as
complement receptor for C3b. The activity of this sub-
group of receptors is enhanced in human PMN when
exposed to endotoxin in a CD14-dependent manner [50].
The CD11c/CD18 complex, though function is unclear, is
found in many cells including monocytes and may be the
main alternative to CD14 involved in the identification of
endotoxin [51]. CHO cells transfected with CD11c/CD18
were able to recognize and respond to endotoxin indepen-
dent of CD14 even at low concentration in the range of 1
ng/ml [46]. However this is not a necessary condition
since cells with mCD14 can release pro-inflammatory
cytokines when exposed to endotoxin in the absence of
CD18 receptors [52]. To further support a potential con-
tribution of CD11/CD18 receptors to CD14-independent
signaling, we found decreased superoxide production in
response to PBMC exposure to endotoxin only with the
combined use of CD11b/CD18 and CD11c/CD18 antibo-
dies, but not when used individually. Further studies are
warranted to elucidate the contributory mechanisms of
specific serum proteins and receptor subtypes in CD14-
dependent and independent endotoxin signaling.
Table 1 Endotoxin-dependent IL-8 release and ROS
formation by freshly isolated human monocytes is
regulated by distinct signaling pathways
IL-8 Release ROS Production
LBP-independent LBP-dependent
CD14-dependent Partially CD14-dependent
TLR4-dependent TLR4-independent
Inhibited by lovastatin Inhibited by lovastatin
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The endotoxin-CD14 complex initiates signaling by
engaging TLR4 and the co-receptor MD-2 [5,32,53].
Cellular responses to endotoxin are partly determined
by concentration and type of LPS (rough or smooth),
length of exposure, as well as the affected cell type.
Together these factors determine cell surface receptor
expression, cytokine production, and ROS generation
[54,55]. Recent evidence suggests that TLR4 plays an
important role in atherogenesis [56]. Specifically, the
Asp299Gly polymorphism, which attenuates endotoxin
signaling, is associated with a decreased risk of athero-
sclerosis [57]. TLR4 function has been widely studied in
monocytes and macrophages and was recently examined
in human blood vessels [27] and human coronary artery
endothelial and smooth muscle cells [3] by our labora-
tory. Endotoxin stimulates ROS production in non-
immune cells through a direct interaction between
TLR4 and NOX4 [58,59]. However, we found that while
LPS-induced IL-8 release by human monocytes was
TLR4-dependent (i.e., blocked by HTA-125), superoxide
formation was largely TLR4-independent (Table 1). This
suggests that activation of the NADPH oxidase by LPS
is mediated through alternative receptors in human
monocytes. A potential candidate pathway includes the
MAC1 receptor, which is expressed by monocytes [60]
and mediates endotoxin-dependent ROS formation in
microglial cells [61]. Table 1 also summarizes the effects
of lovastatin treatment. Our studies with lovastatin pro-
vide additional evidence for the anti-inflammatory
effects of these compounds. Given the important role
that monocyte activation is believed to play in acute
coronary syndromes, our findings may also help to
explain the significant reductions in coronary events
observed in patients taking statins.
Taken together, our results suggest that two important
pro-inflammatory responses to low concentrations of
endotoxin, IL-8 release and superoxide production, are
activated by two distinct signaling pathways in human
PBMC. To our knowledge, this is the first study that
evaluates the presence of alternative signaling pathways
in freshly isolated human PBMC from healthy donors
that are exposed to clinically relevant endotoxin levels.
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